The company reported promising early Phase 2 data for its weight-loss drug candidate, MariTide, showing patients maintained weight loss with less frequent dosing, a potential advantage over rivals. The CEO highlighted 2026 as a pivotal 'springboard year' driven by significant upcoming clinical data, with plans to advance MariTide into Phase 3 trials. A separate bullish analyst report suggested the stock may be significantly undervalued relative to a fair value estimate. The company also announced a research collaboration to study real-world patient experiences with obesity treatments.